Picture EBD Group Global Partnering Four Events One Price 650x80
Organisation › Details

Aprea AB

Aprea Therapeutics, Inc. is a biopharmaceutical company headquartered in Boston, Massachusetts with research facilities in Stockholm, Sweden, focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53. The Company’s lead product candidate is eprenetapopt (APR-246), a small molecule in clinical development for hematologic malignancies and solid tumors. Eprenetapopt has received Breakthrough Therapy, Orphan Drug and Fast Track designations from the FDA for myelodysplastic syndromes (MDS), Fast Track designation from the FDA for acute myeloid leukemia (AML), and Orphan Drug designation from the European Commission for MDS, AML and ovarian cancer. APR-548, a next generation small molecule reactivator of mutant p53, is being developed for oral administration. *


Period Start 2003-01-01 splitoff
  Predecessor Karolinska Institutet
Products Industry cancer drug
  Industry 2 eprenetapopt (APR-246)
Persons Person Björklund, Ulf (Aprea 201112 CEO)
  Person 2 Seizinger, Bernd R. (GPC Biotech 199810– CEO before BMS Pharma Research Institute)
Region Region Solna
  Country Sweden
  Street 16 Nobels väg
Karolinska Institutet Science Park (KISP)
  City 171 65 Solna
  Tel +46-8-5088-4504
    Address record changed: 2020-12-30
Basic data Employees n. a.
    * Document for �About Section�: Aprea Therapeutics, Inc.. (12/28/20). "Press Release: Aprea Therapeutics Announces Results of Primary Endpoint from Phase 3 Trial of Eprenetapopt in TP53 Mutant Myelodysplastic Syndromes (MDS)". Boston, MA.
Record changed: 2020-12-30


Picture [iito] Plain Stupid Simple 650x80px

More documents for Aprea AB

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture [iito] Back into Ad 650x80px

» top